Ipsen
Ipsen S.A., a global biopharmaceutical group headquartered in France, has established itself as a leader in the healthcare industry since its founding in 1929. With a strong presence in Europe, North America, and Asia, Ipsen focuses on innovative treatments in oncology, neuroscience, and rare diseases. The company is renowned for its core products, including Somatuline® and Cabometyx®, which are distinguished by their unique mechanisms of action and efficacy in treating complex conditions. Ipsen's commitment to research and development has led to significant milestones, including the expansion of its product portfolio and strategic partnerships that enhance its market position. Recognised for its dedication to patient care and innovation, Ipsen continues to make strides in the biopharmaceutical sector, contributing to advancements that improve the quality of life for patients worldwide.
DitchCarbon Score
How does Ipsen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ipsen's score of 85 is higher than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ipsen's reported carbon emissions
In 2024, Ipsen reported significant carbon emissions, with Scope 1 emissions totalling approximately 10,138,000 kg CO2e globally, and 2,659,700 kg CO2e in France. The company also disclosed Scope 2 emissions of about 289,000 kg CO2e globally, alongside various regional emissions, including 2,627,100 kg CO2e in the UK and 1,300 kg CO2e in Colombia. Ipsen has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 50% by 2030, using 2019 as the baseline year. Additionally, the company targets a 20% reduction in Scope 3 emissions within the same timeframe. These targets are aligned with the Science Based Targets initiative (SBTi) and contribute to the Paris Agreement's goal of limiting global warming to 1.5°C. Looking further ahead, Ipsen has committed to achieving net-zero emissions across all scopes by 2045, with a target to reduce absolute Scope 1, 2, and 3 emissions by at least 90% from the 2019 baseline. This comprehensive approach underscores Ipsen's dedication to sustainability and climate action within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2019 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 13,024,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 15,399,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000 | 000,000 |
| Scope 3 | - | 00,000,000 | 00,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | - | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ipsen is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
